Systematic characterization of human gut microbiome-secreted molecules by integrated multi-omics | ISME Communications
Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's Disease - ScienceDirect
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease | Nature Genetics
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies | Biomarkers in Medicine
Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder | Neurology
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease | Neurology
The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker | PNAS
Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study - Mollenhauer - 2019 - Journal of Neurochemistry - Wiley Online Library
JCM | Free Full-Text | Blood Neurofilament Light Chain in Parkinson's Disease: Comparability between Parkinson's Progression Markers Initiative (PPMI) and Asian Cohorts | HTML
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis | Biomarkers in Medicine
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort - Majbour - - Movement Disorders - Wiley Online Library
Dr. Brit Mollenhauer, Paracelsus-Elena-Klinik – supported researcher | JPND
Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease - ScienceDirect
A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol | Nature Communications
Cells | Free Full-Text | Protein Binding Partners of Dysregulated miRNAs in Parkinson's Disease Serum | HTML
Full article: Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype
Frontiers | Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort | Neurology
A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design and baseline data | medRxiv
Frontiers | LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort | Neurology
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases | Nature Reviews Neurology
